Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial
Keywords: doxycycline; erlotinib; folliculitis; non-small-cell lung cancer; rash; AE; adverse event; CI; confidence interval; CONSORT; CONsolidated Standards Of Reporting Trials; CTCAE; Common Terminology Criteria for Adverse Events; CYTAR; CYcline and TARceva; DI;